DEVON, Pa.– COEUS Holdings and its subsidiaries (“COEUS”), together a leading health outcomes, contracting, technology, and commercial insights consulting firm, today announced it has appointed Dean Hakanson, MD, to the role of Chief Medical Officer. He joins COEUS following a period of rapid expansion during which the company has experienced double-digit year-over-year growth in both revenue and head count for the last ten years.
In this role, Dr. Hakanson will drive advancements in COEUS’ expertise and service capabilities for the company’s work in novel, Value-Based Healthcare (VBH) by leveraging real-world data (RWD) to identify areas of opportunity for improving patient health outcomes. Dr. Hakanson’s expertise will be further utilized to develop new Medical Affairs offerings that will assist clients’ clinical and medical staff members in demonstrating their value and contributions toward advancing overall business within biopharmaceutical companies.
“We’re thrilled to have Dr. Hakanson join COEUS as our Chief Medical Officer – a critical position – as we continue our rapid growth,” said Marc Hixson, CEO, at COEUS. “Patient access to innovation is a key part of COEUS’ Medical Affairs’ strategy – a strategy that links to Managed Market’s goal of attaining formulary position through a targeted medical communications strategy that ensures ‘the right patient gets the right therapy at the right time’.”
With a 25+ year distinguished career as an executive in the biopharma industry, Dr. Hakanson’s experience spans work with startups as well as large biotech organizations. Dr. Hakanson has held many leadership positions, including Partner at ZS Associates, CMO at Otonomy, VP and Head of US Medical Affairs at Gilead, and VP of HEOR at Novartis, and has served as an executive leader at BMS, Genentech, and GSK. He is a recognized leader in health policy and economics with past board membership in the National Pharmaceutical Council and the Leonard D. Schaeffer Center for Health Policy and Economics, at the University of Southern California.
“I am eager to drive and contribute to COEUS’ many endeavors as the company continues to transform the model for drug and therapy delivery for its clients,” said Dr. Hakanson. “COEUS is uniquely positioned to enable patient access to innovative medicines – including cell/genetic, oncological, and rare disease therapies – that demand actionable insights and novel solutions for Managed Markets, Value & Access, and Medical Affairs functions. I look forward to contributing to the company’s progress and growth.”
As a board-certified anesthesiologist, Dr. Hakanson’s clinical practice has focused on surgical and ICU patient care. He is recognized across the industry as skilled in creating opportunities and alignment with senior leadership and in developing successful strategic partnerships across the healthcare ecosystem. These partnerships include stakeholders within healthcare payer organizations, organized providers, pharmaceutical manufacturers, and patient advocacy organizations. Dr. Hakanson is a Diplomate of the American Board of Anesthesiology and the American Medical Association and is currently licensed to practice medicine in California.
